TABLE 3.

Univariate and multivariate logistic regression analysis for 3-month poor functional outcome in sensitivity analysis.

Variables	Crude model		Model 1		Model 2		Model 3
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
SHR1 Q1 (< 1.02)	Ref.		Ref.		Ref.		Ref.
SHR1 Q2 (1.02–1.15)	0.838 (0.349–2.012)	0.692	0.582 (0.222–1.527)	0.272	0.708 (0.212–2.356)	0.573	0.765 (0.224–2.611)	0.669
SHR1 Q3 (1.15–1.44)	0.902 (0.380–2.141)	0.816	0.675 (0.268–1.699)	0.404	1.096 (0.352–3.411)	0.874	1.179 (0.366–3.795)	0.782
SHR1 Q4 (> 1.44)	2.921 (1.219–6.998)	0.016	2.562 (0.994–6.599)	0.051	2.789 (0.898–8.663)	0.076	2.879 (0.903–9.184)	0.074
SHR1 (> 1.35 vs. ≤ 1.35)	3.000 (1.528–5.889)	0.001	2.955 (1.427–6.116)	0.004	2.922 (1.220–6.998)	0.016	2.934 (1.198–7.189)	0.019
SHR1 (per 0.1-point increase)	1.179 (1.045–1.329)	0.007	1.173 (1.019–1.337)	0.017	1.200 (1.027–1.402)	0.021	1.203 (1.026–1.411)	0.023
SHR2 Q1 (< 0.79)	Ref.		Ref.		Ref.		Ref.
SHR2 Q2 (0.79–0.89)	3.833 (1.169–12.567)	0.027	3.012 (0.884–10.258)	0.078	4.772 (1.035–21.994)	0.045	5.311 (1.115–25.294)	0.036
SHR2 Q3 (0.89–1.03)	9.274 (2.938–29.276)	<0.001	8.168 (2.478–26.922)	0.001	10.845 (2.377–49.479)	0.002	13.609 (2.807–65.982)	0.001
SHR2 Q4 (> 1.03)	9.409 (2.844–31.134)	<0.001	8.201 (2.363–28.457)	0.001	10.204 (2.134–48.784)	0.004	16.976 (3.000–96.054)	0.001
SHR2 (> 0.92 vs. ≤ 0.92)	5.557 (2.897–10.657)	<0.001	5.475 (2.718–11.209)	<0.001	4.682 (1.997–10.977)	<0.001	6.325 (2.524–15.850)	<0.001
SHR2 (per 0.1-point increase)	1.560 (1.260–1.932)	<0.001	1.576 (1.246–1.995)	<0.001	1.509 (1.145–1.987)	0.003	1.770 (1.268–2.471)	0.001

Model 1, adjusted for age and sex.

Model 2, adjusted for age, sex, current smoking, hyperlipidemia, atrial fibrillation, prior stroke, systolic blood pressure (SBP), and NIHSS at admission.

Model 3, adjusted for covariates from Model 2 and further adjusted for body mass index (BMI), diabetes, and triglyceride-glucose index (TyG).

In the sensitivity analysis, we adopted the previously established groups in Table 2 and excluded participants with top 5% SHR, bottom 5% SHR, or without lipid data.

SHR, stress hyperglycemia ratio.